product summary
Loading...
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
secondary antibody
product name :
Rat IgE Kappa
catalog :
PRP07A
quantity :
0.1 mg
price :
324 USD
more info or order :
product information
EntityType :
Purified Protein
EntityCategory :
Antigens and Lysates
Region :
KAPPA
ProductCode :
PRP07A
Description :
Rat IgE Kappa
Specificity :
IgE
TargetSpecies :
Rat
Format :
Purified
Isotypes :
IgE
Applications :
E
ApplicationTypes :
ELISA
Clone :
IR162
Quantity :
0.1 mg
QuantityValue :
0.1
QuantityType :
mg
GOAccessions :
GO:0003823
GOTerms :
antigen binding
UniprotAccessions :
P01855
Gene :
Ighe
GeneID URL :
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=299351
EntityFormats :
Purified
UNSPSC :
12352202
Concentration :
IgE concentration 1.0 mg/ml
ProductForm :
IgE purified (myeloma IR162) - liquid
PriceGBP :
185
PriceEUR :
247
PriceUSD :
324 USD
PriceCHF :
269
PriceSEK :
2754
PriceNOK :
2841
PriceDKK :
1843
more info or order :
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.